Phenolic thiazoles as novel orally-active neuroprotective agents

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 1, 2004, Pages 157-160

  Harnett, Jeremiah J ^a   Roubert, Veronique ^a   Dolo, Christine ^a   Charnet, Christelle ^a   Spinnewyn, Brigitte ^a   Cornet, Sylvie ^a   Rolland, Alain ^a   Marin, Jean Gregoire ^a   Bigg, Dennis ^a   Chabrier, Pierre E ^a  

^a Institut Henri Beaufour   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; NEUROPROTECTIVE AGENT; PHENOL DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG SYNTHESIS; MITOCHONDRION; MOUSE; NEUROPROTECTION; NONHUMAN;

EID: 0346256829     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.077     Document Type: Article

References (24)

1. (a) Alexi T., Borlongan C.V., Faull R.L., Williams C.E., Clark R.G., Gluckman P.D., Hughes P.E. Prog. Neurobiol. 60:2000;409.
2. (b) Albers D.S., Beal M.F. J. Neural. Transm. 59:2000;133.
3. (c) Beal M.F. Biochim. Biophys. Acta. 1366:1998;211.
4. Powis G., Briehl M. J. Pharmacol. Ther. 68:1995;149.
5. Hosokawa M., Ueno M. Neurobiol. Aging. 2:1999;117.
6. (a) Floyd R. Free. Radical. Biol. Med. 26:1999;1346.
7. (b) Gonzalez-Scarano F., Baltuch G. Annu. Rev. Neurosci. 22:1999;219.
8. (c) Hirsch E.C., Hunot S., Damier P., Faucheux B. Ann. Neurol. 44:1998;S115.
9. (d) McGeer P.L., McGeer E.G. Alzheimer. Dis. Assoc. Disord. 12(Suppl. 2):1998;S1.
10. (a) Harnett J.J., Auguet M., Viossat I., Dolo C., Bigg D., Chabrier P.-E. Biorg. Med. Chem. Lett. 12:2002;1439
11. (b) Chabrier, P. E.; Roubert. V.; Harnett, J. J.; Cornet, C.; Delaflotte, S.; Charnet, C.; Spinnewyn. B.; Auguet, M. New Neuroprotective Agents Are Potent Inhibitors of Mitochondrial Toxins: In Vivo and In Vitro Studies; 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, Nov. 10-15, 2001.
12. (c) Spinnewyn B., Cornet S., Auguet M., Chabrier P.-E. J. Cereb. Blood Flow Metab. 19:1999;139.
13. Esterbauer H., Cheeseman K.H. Methods Enzymol. 186:1990;407.
14. (a) Edaravone (MCI-186, Radicut™): Graul A., Castane J. Drugs Future. 21:1996;1014.
15. (b) Tabrizchi R. Curr. Opin. Investig. Drugs. 1:2000;347.
16. (a) Nicklas W.J., Vyas I., Heikkila R.E. Life. Sci. 36:1985;2503
17. (b) Webb. J. L. In Enzymatic and Metabolic Inhibitors; Academic: New York, 1966.
18. (c) Araki H., Karasawa Y., Nojiri M., Aihara H. Methods Find. Exp. Clin. Pharmacol. 10:1988;349.
19. 100). The mice were then observed for 120 s, noting the survival time, which represented the time between KCN injection and the last gasp.
20. (a) Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. Proc. Natl. Acad. Sci. U.S.A. 80:1983;4546.
21. (b) Langston J.W., Forno L.S., Rebert C.S., Irwin I. Brain. Res. 292:1984;390
22. (c) Tetrud J.W., Langston J.W. Science. 245:1989;519.
23. 4, 0.1 mM EDTA, 2.1 mM TEA and 1.25 mM sodium octane sulfate pH=3.7 and 10% methanol. Methanol was added after pH adjustment.
24. Klivenyi P., Ferrante R.J., Gardian G., Browne S., Chabrier P.-E., Beal M.F. J. Neurochem. 86:2003;267.